Clinical Trials Sponsored by HbO2 Therapeutics LLC

Total 408 results

Cloudbreak Therapeutics, LLC

Recruiting

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Pterygium

United States, China, India, Australia, New Zealand
Cerevel Therapeutics, LLC

Recruiting

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary, Puerto Rico, Ukraine
Cerevel Therapeutics, LLC

Recruiting

A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Schizophrenia

United States, Bulgaria, Hungary
Rapa Therapeutics LLC

Recruiting

RAPA-201 Therapy of Solid Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Solid Tumor | Bladder Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Malignant Melanoma | Carcinoma of Unknown Primary | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of Oral Cavity | Squamous Cell Carcinoma of Nasopharynx and other conditions

United States
Grifols Therapeutics LLC

Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

United States
Expression Therapeutics, LLC

Not yet recruiting

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Hemophilia A
Cerevel Therapeutics, LLC

Active, not recruiting

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Seizures

United States, Spain, Australia, Poland, Ukraine, Serbia
Cerevel Therapeutics, LLC

Completed

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

Healthy Participants

United States
Cloudbreak Therapeutics, LLC

Completed

Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction

Meibomian Gland Dysfunction

United States
Cerevel Therapeutics, LLC

Completed

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

Parkinson Disease

Germany, Spain, United States, Australia, Bulgaria, Czechia, France, Israel, Italy, Poland, Ukraine, Serbia
Cerevel Therapeutics, LLC

Completed

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Renal Impairment

United States
Grifols Therapeutics LLC

Enrolling by invitation

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency (SPARTA-OLE)

Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency

United States, New Zealand, Denmark, Australia, Finland, Estonia, Canada, Poland, Russian Federation, Sweden, France
Cerevel Therapeutics, LLC

Completed

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

Parkinson Disease

United States
Grifols Therapeutics LLC

Completed

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

Primary Immunodeficiency

United States
Cerevel Therapeutics, LLC

Completed

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Schizophrenia

Belgium, United States
Cerevel Therapeutics, LLC

Completed

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

Parkinson Disease

United States
Grifols Therapeutics LLC

Terminated

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

COVID-19

United States, Brazil, Chile, Colombia, Mexico
Cerevel Therapeutics, LLC

Completed

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

Major Depressive Disorder

United States
Cerevel Therapeutics, LLC

Completed

A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects

Panic Disorder

Netherlands
Oryn Therapeutics, LLC

Completed

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

Rheumatoid Arthritis

United States
Allodynic Therapeutics, LLC

Completed

Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

Migraine With and Without Aura

United States
Cerevel Therapeutics, LLC

Terminated

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

Substance Use Disorders (SUD)

United States
Grifols Therapeutics LLC

Completed

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

Myasthenia Gravis Exacerbations

Belgium, Poland, Canada, Argentina, Estonia, France, Hungary, Romania, Czechia, Latvia, Russian Federation, South Africa
Cloudbreak Therapeutics, LLC

Completed

Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium (Pterygium)

Pterygium

United States
Olatec Therapeutics LLC

Completed

Study of Dapansutrile Capsules in Heart Failure

Systolic Heart Failure

United States
Trius Therapeutics LLC

Completed

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Skin Diseases, Infectious | Skin Diseases, Bacterial

United States
Trius Therapeutics LLC

Completed

Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

Healthy

United States
Grifols Therapeutics LLC

Completed

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

United States, Canada
Grifols Therapeutics LLC

Completed

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Myasthenia Gravis, Generalized

United States, Belgium, Czechia, Canada, Estonia, Lithuania, France, Germany, Hungary, Poland
Grifols Therapeutics LLC

Terminated

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

United States
Trius Therapeutics LLC

Completed

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. (ABSSSI)

Skin and Subcutaneous Tissue Bacterial Infections

United States, Argentina, Brazil, Canada, Czechia, Germany, Hungary, Latvia, Peru, Slovakia, Ukraine
Trius Therapeutics LLC

Completed

A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response

Healthy Subjects

United States
Trius Therapeutics LLC

Completed

Food Effects of Single Oral Dose of 600mg TR-701

Healthy

United States
Trius Therapeutics LLC

Completed

Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

Healthy Subjects

United States
Trius Therapeutics LLC

Completed

Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults (SAD/MAD)

Healthy Subjects

United States
Minneamrita Therapeutics LLC

Completed

Study of Minnelide™ in Patients With Advanced GI Tumors

Advanced Gastrointestinal Tumors

United States
Grifols Therapeutics LLC

Completed

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

Acute Peripheral Arterial Occlusion

United States, Peru, Belgium, Bulgaria, Czech Republic, Germany, India, Poland, Romania, Serbia, Slovakia, Spain
Grifols Therapeutics LLC

Completed

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion (PRIORITY)

Arterial Occlusive Diseases

United States
Trius Therapeutics LLC

Completed

A PK and Safety Study in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Trius Therapeutics LLC

Completed

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

Healthy

United States
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (PRIVIG)

Multiple Sclerosis, Relapsing-Remitting

Canada, Israel, United States, Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovakia, Sweden, United Kingdom
Grifols Therapeutics LLC

Completed

Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration

Macular Degeneration

Germany
Grifols Therapeutics LLC

Terminated

Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels

Tetanus

United States
Optimum Therapeutics, LLC

Terminated

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Grifols Therapeutics LLC

Completed

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

Immunologic Deficiency Syndrome

United States, Canada
Grifols Therapeutics LLC

Completed

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Alpha 1-Antitrypsin Deficiency

Denmark, Sweden, United Kingdom
Allodynic Therapeutics, LLC

Withdrawn

Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain (AFP)

Atypical Facial Pain | Persistent Idiopathic Facial Pain | Atypical Trigeminal Neuralgia | Neuropathic Orofacial Pain | Neuropathic Facial Pain

United States
Dart Therapeutics. LLC

Completed

DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls

Duchenne Muscular Dystrophy

United States
Cerevel Therapeutics, LLC

Recruiting

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

Healthy Participants

United States
Cerevel Therapeutics, LLC

Not yet recruiting

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

Healthy Participants

Clinical Trials Sponsored by HbO2 Therapeutics LLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations